# The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma

> **NCT01820858** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ding Ma** · enrollment: 300 (estimated)

## Conditions studied

- Endometrial Neoplasms

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Paraplatin (Carboplatin Injection)
- **RADIATION:** Pelvic Radiation
- **RADIATION:** Vaginal Brachytherapy 1
- **RADIATION:** Vaginal brachytherapy 2

## Key facts

- **NCT ID:** NCT01820858
- **Lead sponsor:** Ding Ma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-11
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820858, "The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01820858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*